Efficacy and safety of corticosteroids for the treatment of community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials

Cheema, Huzaifa Ahmad, Musheer, Adeena, Ejaz, Arooba, Paracha, Anousheh Awais, Shahid, Abia, Rehman, Mohammad Ebad Ur, Hermis, Alaa Hamza, Singh, Harpreet, Duric, Natalie, Ahmad, Faran, Ahmad, Sharjeel, Torres, Antoni and Szakmany, Tamas ORCID: https://orcid.org/0000-0003-3632-8844 2024. Efficacy and safety of corticosteroids for the treatment of community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials. Journal of Critical Care 80 , 154507. 10.1016/j.jcrc.2023.154507

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (3MB) | Preview

Abstract

Background The role of corticosteroids in the treatment of community-acquired pneumonia (CAP) remains uncertain. We conducted an updated meta-analysis to investigate the effectiveness and potential effect modifiers of adjunctive corticosteroids in patients with CAP. Methods The protocol of this meta-analysis was registered with PROSPERO (CRD42022354920). We searched MEDLINE, Embase, the Cochrane Library and trial registers from inception till March 2023 to identify randomized controlled trials (RCTs) investigating corticosteroids in adult patients with CAP. Our primary outcome was the risk of all-cause mortality within 30 days after randomization (if not reported at day 30, we extracted the outcome closest to 30 days). Risk ratios (RR) and mean differences (MDs) were pooled under a random-effects model. Results Fifteen RCTs (n = 3252 patients) were included in this review. Corticosteroids reduced the risk of all-cause mortality in CAP patients (RR: 0.69, 95% CI: 0.53–0.89; high certainty). This significant result was restricted to hydrocortisone therapy and patients with severe CAP. Additionally, younger patients demonstrated a greater reduction in mortality. Corticosteroids reduced the incidence of shock and the need for mechanical ventilation (MV), and decreased the length of hospital and ICU stay (moderate certainty). Conclusions Corticosteroids reduce the risk of all-cause mortality, especially in younger patients receiving hydrocortisone, and probably decrease the need for MV, the incidence of shock, and the length of hospital and ICU stay in patients with CAP. Our findings indicate that patients with CAP, especially severe CAP, will benefit from adjunctive corticosteroid therapy.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier
ISSN:	0883-9441
Date of First Compliant Deposit:	2 January 2024
Date of Acceptance:	12 December 2023
Last Modified:	09 Jan 2024 14:45
URI:	https://orca.cardiff.ac.uk/id/eprint/165120

Actions (repository staff only)

Edit Item